mpox
Conditions
Interventions
None listed
Sponsors
Japan Institute for Health Security(JIHS)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Subjects who have obtained written consent from the person himself/herself or his/her agent regarding participation in the research 2) Men and women aged 1 year or older at the time of obtaining consent 3) Subjects who plan to receive or have received the dry cell culture smallpox vaccine LC16 "KMB" for the purpose of preventing mpox within 14 days after exposure to mpox patients.
Exclusion criteria
Exclusion criteria: 1) Subjects who have developed mpox at the time of smallpox vaccine innoculation 2) Subjects whose smallpox vaccine innoculation site and timing are unknown 3) Subjects who are judged inappropriate for inclusion in the study by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of participants developed mpox within 28 days after innoculation among close contacts who received smallpox vaccine (LC16 KMB) within 14 days after exposure | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of participants developed major skin reactions up to 14 days after innoculation The proportion of participants developed severe mpox up to 28 days after innoculation Safety up to 28 days after innoculation | — |
Countries
Japan
Contacts
Public ContactMugen Ujiie
Japan Institute for Health Security(JIHS) National Center for Global Health and Medicine Disease control and prevention center
Outcome results
None listed